LBA88Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER
ConclusionsDespite a PFR at 12 weeks lower than expected, this randomized non comparative study shows a promising signal of benefit of REG in relapsed CS, with a median of PFS of 19 weeks and, an acceptable toxicity.Clinical trial identificationEudraCT: 2013-003910-42, NCT02389244.Legal entity responsible for the studyUNICANCER.FundingBayer HealthCare SAS.DisclosureF. Duffaud: Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Lilly; Travel / Accommodation / Expenses: Pharmamar; Travel / Accommodation / Expenses: Leo Pharma. J. Blay: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): GSK. O. Mir: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Blueprint Medicines; Honoraria ...
ConclusionOur analysis provided strong evidence to indicate a causal relationship between WC and increased risk of CHD.
ConclusionNEAT1 upregulateIGF2 expression through absorbing miR ‐185‐5p to enhances the migration and invasion of colon cancer cells.
Discussion and conclusionsA schema showing the time from initiation of therapy at which specific antineoplastic agents can cause significant levels of genetic damage in conceptuses and live offspring was developed. The estimates and methods for computing the level of such risk from an individual patient's treatment regimen will enable patients and counselors to make informed decisions on the use of spermatozoa or continuation of a pregnancy.
Publication date: Available online 26 February 2020Source: European UrologyAuthor(s): Wei Liu, Xiaoping Liu, Sheng Li
The objective of this study was to examine the effect of metabolic syndrome on 30-day postoperative complications following corrective surgery for the adult spinal deformity (ASD). Summary of Background Data: Metabolic syndrome has been shown to increase the risk of cardiovascular morbidity and mortality. Few studies have examined the effect of metabolic syndrome on patients with ASD undergoing surgery. Materials and Methods: We performed a retrospective cohort study of patients who underwent spinal fusion for ASD. Patients were divided into 2 groups based on the presence or absence of metabolic syndrome, which was d...
AbstractBackgroundAcute vasoreactivity testing (AVT) which reflects the compliance of the pulmonary vascular bed has been proven to be of prognostic value. The purpose of the present study is to explore the sex differences of hemodynamics during the AVT and their impact on event ‐free survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH).MethodsEighty ‐six patients underwent a right heart catheterization and AVT at Shanghai Pulmonary Hospital from February 2009 to February 2018. Univariate and multiple stepwise regression analysis were performed to determine the predictors of independent event...
Conditions: Hypertension; Salt; Excess Interventions: Device: Salt-meter; Behavioral: Education Sponsor: Mahidol University Active, not recruiting
Conditions: Pre-hypertension; Hypertension Intervention: Behavioral: WOW Intervention Sponsor: Johns Hopkins University Not yet recruiting
Conditions: Diabetes Mellitus, Type 2; Diabetes; Diabetes type2; Type2 Diabetes; Type 2 Diabetes; Type II Diabetes; Hypertension; High Blood Pressure Interventions: Other: DASH4D diet; Other: comparison diet; Other: higher sodium; Other: lower sodium Sponsors: Johns Hopkins University; Beth Israel Deaconess Medical Center Not yet recruiting
Conditions: Acute Respiratory Distress Syndrome; Acute Kidney Injury; Prone Position; Intra-Abdominal Hypertension Intervention: Other: Prone position Sponsors: University Hospital, Grenoble; French Society for Intensive Care; Act For Chronic Diseases Not yet recruiting
More News: AstraZeneca | Bone Cancers | Cancer & Oncology | Chemotherapy | Chondrosarcoma | Chordoma | Clinical Trials | Ewing's Sarcoma | France Health | Grants | Hypertension | Legislation | Liver | Osteosarcoma | Pfizer | Pharmaceuticals | Sarcomas | Study | Thrombocytopenia | Toxicology | Urology & Nephrology